久盛电气 reported revenue of ¥0.83B for the period ended 2026-06-30, -31.5% year on year. Net income was ¥0.02B, a 2.2% net margin on a 12.0% gross margin. Free cash flow for the period was ¥-0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.83B | -31.5% |
| Gross profit | ¥0.10B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | +65.7% |
| Gross margin | 12.0% | Net margin 2.2% |
| Revenue Q/Q | +16.8% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.73B | 88.0% |
| R&D | ¥0.03B | 3.6% |
| SG&A | ¥0.05B | 5.9% |
| Tax & other | ¥0.00B | 0.3% |
| Item | Amount |
|---|---|
| Total assets | ¥3.36B |
| Total liabilities | ¥2.32B |
| Shareholders' equity | ¥1.04B |
| Equity / assets | 30.9% |
| Operating cash flow | ¥-0.04B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.05B |
| Cash conversion (OCF / net income) | -85% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
百胜智能 ・ 亚康股份 ・ 鸿富瀚 ・ 可孚医疗 ・ 戎美股份 ・ 拓新药业 ・ 华润材料 ・ 深城交 ・ 争光股份 ・ 华兰股份 ・ 广立微 ・ 百诚医药
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies